BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 18722765)

  • 1. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Balaguer F; Sempere L; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Pons E; Payá A; Alenda C;
    Eur J Cancer; 2009 Feb; 45(3):365-73. PubMed ID: 18722765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
    Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
    Gal R; Sadikov E; Sulkes J; Klein B; Koren R
    Dis Colon Rectum; 2004 Jul; 47(7):1216-24. PubMed ID: 15148649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer.
    Ahmed IA; Kelly SB; Anderson JJ; Angus B; Challen C; Lunec J
    Colorectal Dis; 2008 May; 10(4):344-51. PubMed ID: 17949449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
    Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
    Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer.
    Isogai A; Nagaya M; Matsuoka H; Watanabe T; Tsukikawa S; Kubota S
    Surgery; 2007 Nov; 142(5):741-8. PubMed ID: 17981195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoresponsiveness associated with canonical molecular changes in colorectal adenocarcinomas.
    Kim JC; Roh SA; Cho DH; Kim TW; Yoon SN; Kim CW; Yu CS; Kim SY; Kim YS
    Anticancer Res; 2009 Aug; 29(8):3115-23. PubMed ID: 19661324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
    Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
    Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency.
    Jensen LH; Lindebjerg J; Byriel L; Kolvraa S; Crüger DG
    Colorectal Dis; 2008 Jun; 10(5):490-7. PubMed ID: 17868408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
    Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
    Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle.
    Tejpar S; Saridaki Z; Delorenzi M; Bosman F; Roth AD
    J Natl Cancer Inst; 2011 Jun; 103(11):841-4. PubMed ID: 21597023
    [No Abstract]   [Full Text] [Related]  

  • 16. Adjuvant 5-FU based chemotherapy for colon cancer: match or miss the mismatch?
    D'Incalci M
    Eur J Cancer; 2009 Feb; 45(3):316-7. PubMed ID: 19097881
    [No Abstract]   [Full Text] [Related]  

  • 17. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
    Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
    Alhopuro P; Alazzouzi H; Sammalkorpi H; Dávalos V; Salovaara R; Hemminki A; Järvinen H; Mecklin JP; Schwartz S; Aaltonen LA; Arango D
    Clin Cancer Res; 2005 Sep; 11(17):6311-6. PubMed ID: 16144935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite instability testing and its role in the management of colorectal cancer.
    Kawakami H; Zaanan A; Sinicrope FA
    Curr Treat Options Oncol; 2015 Jul; 16(7):30. PubMed ID: 26031544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.